PGRMC1: an enigmatic heme-binding protein

MR McGuire, PJ Espenshade - Pharmacology & therapeutics, 2023 - Elsevier
Abstract Progesterone Receptor Membrane Component 1 (PGRMC1) is a heme-binding
protein that has been implicated in a wide range of cell and tissue functions, including …

[HTML][HTML] Progestins as anticancer drugs and chemosensitizers, new targets and applications

TA Fedotcheva, NI Fedotcheva, NL Shimanovsky - Pharmaceutics, 2021 - mdpi.com
Progesterone and its synthetic analogues, progestins, participate in the regulation of cell
differentiation, proliferation and cell cycle progression. Progestins are usually applied for …

[HTML][HTML] Progesterone Receptor Membrane Component 1 (PGRMC1) Modulates Tumour Progression, the Immune Microenvironment and the Response to Therapy in …

CA Dumitru, H Schröder, FTA Schäfer, JF Aust… - Cells, 2023 - mdpi.com
Progesterone Receptor Membrane Component 1 (PGRMC1) is a tumour-promoting factor in
several types of cancer but its role in brain tumours is poorly characterized thus far. Our …

[HTML][HTML] Implications of lipid droplets in lung cancer: Associations with drug resistance

C Jin, P Yuan - Oncology letters, 2020 - spandidos-publications.com
Cancer cells usually show different metabolic patterns compared with healthy cells due to
the reprogramming of metabolic processes. The process of lipid metabolism undergoes …

Pleiotropic actions of PGRMC proteins in cancer

JK Pru - Endocrinology, 2022 - academic.oup.com
Progesterone receptor membrane component (PGRMC) proteins play important roles in
tumor growth, progression, and chemoresistance, of which PGRMC1 is the best …

[HTML][HTML] Loss of PGRMC1 delays the progression of hepatocellular carcinoma via suppression of pro-inflammatory immune responses

SR Lee, JG Lee, JH Heo, SL Jo, J Ryu, G Kim, JM Yon… - Cancers, 2021 - mdpi.com
Simple Summary Progesterone receptor membrane component 1 (PGRMC1) and epidermal
growth factor receptor (EGFR) are highly expressed in various cancers. Here, we first …

[HTML][HTML] From targeted therapy to a novel way: Immunogenic cell death in lung cancer

J Xu, Y Xiong, Z Xu, H Xing, L Zhou, X Zhang - Frontiers in Medicine, 2022 - frontiersin.org
Lung cancer (LC) is one of the most incident malignancies and a leading cause of cancer
mortality worldwide. Common tumorigenic drivers of LC mainly include genetic alterations of …

PGRMC1 promotes NSCLC stemness phenotypes by disrupting TRIM56-mediated ubiquitination of AHR

A Guan, Z Dai, C Jiang, J Sun, B Yang, B Xie… - Biochimica et Biophysica …, 2024 - Elsevier
Cancer stem cells (CSCs) are responsible for tumor chemoresistance, and the aryl
hydrocarbon receptor (AHR) is indispensable for maintaining CSC characteristics. Here, we …

[HTML][HTML] Research progress of ginger in the treatment of gastrointestinal tumors

GQ Chen, Y Nan, SC Huang, N Ning… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Cancer seriously endangers human health. Gastrointestinal cancer is the most common and
major malignant tumor, and its morbidity and mortality are gradually increasing. Although …

[HTML][HTML] Identification of the biomarkers and pathological process of heterotopic ossification: weighted gene co-expression network analysis

S Wang, J Tian, J Wang, S Liu, L Ke, C Shang… - Frontiers in …, 2020 - frontiersin.org
Heterotopic ossification (HO) is the formation of abnormal mature lamellar bone in extra-
skeletal sites, including soft tissues and joints, which result in high rates of disability. The …